TY - JOUR
T1 - Multi-strain probiotics during pregnancy in women with obesity influence infant gut microbiome development
T2 - results from a randomized, double-blind placebo-controlled study
AU - Halkjær, Sofie Ingdam
AU - Refslund Danielsen, Malene
AU - de Knegt, Victoria E
AU - Andersen, Lee O'Brien
AU - Stensvold, Christen Rune
AU - Nielsen, Henrik Vedel
AU - Mirsepasi-Lauridsen, Hengameh Chloé
AU - Krogfelt, Karen Angeliki
AU - Cortes, Dina
AU - Petersen, Andreas Munk
PY - 2024
Y1 - 2024
N2 - Probiotics have been described to influence host health and prevent the risk of obesity by gut microbiome (GM) modulation. In a randomized double-blinded placebo-controlled feasibility study, we investigated whether Vivomixx® multi-strain probiotics administered to 50 women with obesity during pregnancy altered the GM composition and perinatal health outcomes of their infants up to 9 months after birth. The mothers and infants were followed up with four visits after birth: at 3 d, and at 3, 6, and 9 months after delivery. The infants were monitored by anthropometric measurements, fecal sample analysis, and questionnaires regarding health and diet.The study setup after birth was feasible, and the women and infants were willing to participate in additional study visits and collection of fecal samples during the 9-month follow-up. In total, 47 newborns were included for microbiome analysis.Maternal prenatal Vivomixx® administration did not alter infant GM diversity nor differential abundance, and the probiotic strains were not vertically transferred. However, the infant GM exhibited a decreased prevalence of the obesity-associated genera, Collinsella, in the probiotic group and of the metabolic health-associated Akkermansia in the placebo group, indicating that indirect community-scale effects of Vivomixx® on the GM of the mothers could be transferred to the infant.Moreover, 3 d after birth, the GM of the infant was influenced by mode of delivery and antibiotics administered during birth. Vaginally delivered infants had increased diversity and relative abundance of the metabolic health-associated Bifidobacterium and Bacteroides while having a decreased relative abundance of Enterococcus compared with infants delivered by cesarean section. Maternal antibiotic administration during birth resulted in a decreased relative abundance of Bifidobacteriumin the GM of the infants. In conclusion, this study observed potential effects on obesity-associated infant GM after maternal probiotic supplementation.
AB - Probiotics have been described to influence host health and prevent the risk of obesity by gut microbiome (GM) modulation. In a randomized double-blinded placebo-controlled feasibility study, we investigated whether Vivomixx® multi-strain probiotics administered to 50 women with obesity during pregnancy altered the GM composition and perinatal health outcomes of their infants up to 9 months after birth. The mothers and infants were followed up with four visits after birth: at 3 d, and at 3, 6, and 9 months after delivery. The infants were monitored by anthropometric measurements, fecal sample analysis, and questionnaires regarding health and diet.The study setup after birth was feasible, and the women and infants were willing to participate in additional study visits and collection of fecal samples during the 9-month follow-up. In total, 47 newborns were included for microbiome analysis.Maternal prenatal Vivomixx® administration did not alter infant GM diversity nor differential abundance, and the probiotic strains were not vertically transferred. However, the infant GM exhibited a decreased prevalence of the obesity-associated genera, Collinsella, in the probiotic group and of the metabolic health-associated Akkermansia in the placebo group, indicating that indirect community-scale effects of Vivomixx® on the GM of the mothers could be transferred to the infant.Moreover, 3 d after birth, the GM of the infant was influenced by mode of delivery and antibiotics administered during birth. Vaginally delivered infants had increased diversity and relative abundance of the metabolic health-associated Bifidobacterium and Bacteroides while having a decreased relative abundance of Enterococcus compared with infants delivered by cesarean section. Maternal antibiotic administration during birth resulted in a decreased relative abundance of Bifidobacteriumin the GM of the infants. In conclusion, this study observed potential effects on obesity-associated infant GM after maternal probiotic supplementation.
KW - Female
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Pregnancy
KW - Cesarean Section
KW - Double-Blind Method
KW - Feces/microbiology
KW - Gastrointestinal Microbiome
KW - Mothers
KW - Obesity
KW - Probiotics/therapeutic use
KW - Feasibility Studies
KW - microbiota
KW - pregnancy
KW - newborn
KW - infant
KW - microbiome
KW - probiotics
UR - http://www.scopus.com/inward/record.url?scp=85189869782&partnerID=8YFLogxK
U2 - 10.1080/19490976.2024.2337968
DO - 10.1080/19490976.2024.2337968
M3 - Journal article
C2 - 38591920
SN - 1949-0976
VL - 16
SP - 2337968
JO - Gut Microbes
JF - Gut Microbes
IS - 1
M1 - 2337968
ER -